December 18, 2017 / 11:51 AM / a month ago

BRIEF-Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy

Dec 18 (Reuters) - Achillion Pharmaceuticals Inc:

* ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY

* ACHILLION PHARMACEUTICALS INC - INITIATED BIOAVAILABILITY STUDY EVALUATING EXTENDED-RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS

* ACHILLION PHARMACEUTICALS INC - INITIATION OF BIOAVAILABILITY STUDY OF EXTENDED RELEASE FORMULATIONS OF ACH-4471 IN HEALTHY VOLUNTEERS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below